More tools:Markets·Screener·Research·Chat

Curis Inc (CRIS) Financial Statements

Curis Inc
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SFR6R1
XNAS · usd
1.20▼ 0.07 (-5.51%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close1.27
Day's Range1.18 – 1.34
52-Week Range0.18 – 6.74
Volume187.0K
Avg Volume251.1K
Share Statistics
Shares Outstanding
Employees24
ExchangeXNAS
Listed2000-08-01
Share count as of August 11, 2026
Loading Income Statement…
Key questions about Curis Inc (CRIS)
What is Curis Inc's Market Cap?
Curis Inc's Market Cap is $2.5M, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's Enterprise Value?
Curis Inc's Enterprise Value is -$2.6M, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's Price / Sales?
Curis Inc's Price / Sales is 0.6×, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's EV / Revenue?
Curis Inc's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's EV / EBITDA?
Curis Inc's EV / EBITDA is 0.3×, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's Revenue (TTM)?
Curis Inc's Revenue (TTM) is $4.3M, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's Net Income (TTM)?
Curis Inc's Net Income (TTM) is -$21.2M, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's EBITDA?
Curis Inc's EBITDA is -$8.7M, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's Diluted EPS (TTM)?
Curis Inc's Diluted EPS (TTM) is -10.12, based on as-reported figures from SEC (XBRL) filings.
What is Curis Inc's EBITDA Margin?
Curis Inc's EBITDA Margin is -201.2%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues, net
YoY growth-100.0%-100.0%-66.0%+8.4%
Operating expenses:
Cost of royalties
Research and development
General and administrative
Total operating expenses
% of revenue——765.2%318.0%
Loss from operations
% of revenue——1724.0%-218.0%
Other income (expense):
Interest income
Expense related to the sale of future royalties
Change in fair value of warrant liabilities——
Total other income (expense)
Net loss
% of revenue——1700.9%-243.4%
Net loss per common share, basic (in dollars per share)
Net loss per common share, diluted (in dollars per share)